ARW ON RNA
“Holy Deliverability, Batman!”: Next-Gen “Heroism” For The mRNA-[X] Space
In the first- of this two-part article, Koeris and I ford through some of the most prominent delivery-vehicle development pain-points that don’t get nearly as much conversation as they should today. Though Koeris did not sugarcoat his concerns with some of our current mRNA delivery/LNP development limitations, the questions he posed and considerations he offered give us clearer direction around where we must pursue more scientific “heroism” in the mRNA space.
OUR EXPERT NETWORK
-
![Four Columns Barcelona Spain-GettyImages-1188394883]( "mRNA: The Fourth Pillar Of Pharmaceutical Innovation And Intervention")
mRNA: The Fourth Pillar Of Pharmaceutical Innovation And InterventionmRNA medicines represent the genesis of a fourth pillar of pharma innovation. While exciting, there are several critical challenges we must solve to strengthen this pillar, including stability and deliverability.
-
![Scientists in lab-GettyImages-1441665026]( "Advancing PSC-based Therapies: The Application of Non-Integrating Engineering Strategies to Improve Directed Differentiation")
Advancing PSC-based Therapies: The Application of Non-Integrating Engineering Strategies to Improve Directed DifferentiationThis article explains why the incorporation of non-integrating, traceless engineering tools in PSC directed differentiation approaches could significantly help streamline the development of allogeneic cell therapies.
-
![bioreactor for cell culture-GettyImages-517743648]( "A Deeper Look At What's Driving Dependence On Biotech Contract Manufacturers")
A Deeper Look At What's Driving Dependence On Biotech Contract ManufacturersAre you struggling to find CDMO capacity? Here are some of the drivers behind the contract manufacturing market's exponential growth.
-
![GettyImages-1418152314]( "Unpacking The Importance Of Lipid Nanoparticle Production Platforms")
Unpacking The Importance Of Lipid Nanoparticle Production PlatformsBatch processing platforms for LNPs lack efficiency, appropriate controls, and yield optimization. Continuous manufacturing platforms may address some of those issues.
-
![Inhalable mRNA vaccine COVID-19 -GettyImages-1623659751]( "A Promising Approach To Develop An Inhalable, Temperature-Stable COVID-19 Vaccine")
A Promising Approach To Develop An Inhalable, Temperature-Stable COVID-19 VaccineThere are limitations to the currently available COVID-19 vaccines. An inhalable dry powder approach offers promising benefits, such as eliminating cold chain requirements, allowing for more widespread immunity.
WEBINARS
MEET ARW
I’ve spent the past 10 years building relationships across the biologics and advanced therapies industry. In addition to hosting conversations and writing thought leadership articles, my goal as the editorial and community director for Advancing RNA is to find creative ways for the RNA (and broader ATMP) space to discuss, debate, and ultimately define a mature RNA therapeutics industry.
Start the conversation by following me on LinkedIn!
FREE EBOOK: MODERNA'S REGULATORY JOURNEY
This collection of articles tells the story of how Moderna brought one of the first mRNA vaccines to the market and has all the makings of a legend we will pass down through generations. However, unlike the legends of King Arthur or The Fountain of Youth, we can celebrate that Moderna’s legendary journey was — and still is — real.
VIRTUAL EVENTS
NEWSLETTER ARCHIVE
- 04.24.24 -- What mRNA Can Learn From Art History
- 04.22.24 -- INDe sgRNA Manufacturing
- 04.18.24 -- Novel Approaches In Chromatography Process Development
- 04.17.24 -- What's In The Vial?! A Meditation On mRNA Control Strategy
- 04.10.24 -- The 3 C's Of mRNA-LNP Raw Material Sourcing
- 04.08.24 -- The Business of Biotech: Leaders in ADC Technologies